Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Rapid CommunicationShort Communication

Validation of uPA/SCID Mouse with Humanized Liver as a Human Liver Model: Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases by LC-MS/MS

Sumio Ohtsuki, Hirotaka Kawakami, Tae Inoue, Kenji Nakamura, Chise Tateno, Yuki Katsukura, Wataru Obuchi, Yasuo Uchida, Junichi Kamiie, Toru Horie and Tetsuya Terasaki
Drug Metabolism and Disposition June 2014, 42 (6) 1039-1043; DOI: https://doi.org/10.1124/dmd.114.057646
Sumio Ohtsuki
Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan (S.O., K.N.); Laboratory of Veterinary Pathology, School of Veterinary Medicine, Azabu University, Kanagawa, Japan (H.K., J.K.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (T.I, Y.K., W.O., Y.U., T.T.); PhoenixBio, Co., Ltd., Hiroshima, Japan (C.T.); DeThree Research Laboratory Inc., Ibaraki, Japan (T.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hirotaka Kawakami
Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan (S.O., K.N.); Laboratory of Veterinary Pathology, School of Veterinary Medicine, Azabu University, Kanagawa, Japan (H.K., J.K.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (T.I, Y.K., W.O., Y.U., T.T.); PhoenixBio, Co., Ltd., Hiroshima, Japan (C.T.); DeThree Research Laboratory Inc., Ibaraki, Japan (T.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tae Inoue
Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan (S.O., K.N.); Laboratory of Veterinary Pathology, School of Veterinary Medicine, Azabu University, Kanagawa, Japan (H.K., J.K.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (T.I, Y.K., W.O., Y.U., T.T.); PhoenixBio, Co., Ltd., Hiroshima, Japan (C.T.); DeThree Research Laboratory Inc., Ibaraki, Japan (T.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenji Nakamura
Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan (S.O., K.N.); Laboratory of Veterinary Pathology, School of Veterinary Medicine, Azabu University, Kanagawa, Japan (H.K., J.K.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (T.I, Y.K., W.O., Y.U., T.T.); PhoenixBio, Co., Ltd., Hiroshima, Japan (C.T.); DeThree Research Laboratory Inc., Ibaraki, Japan (T.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chise Tateno
Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan (S.O., K.N.); Laboratory of Veterinary Pathology, School of Veterinary Medicine, Azabu University, Kanagawa, Japan (H.K., J.K.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (T.I, Y.K., W.O., Y.U., T.T.); PhoenixBio, Co., Ltd., Hiroshima, Japan (C.T.); DeThree Research Laboratory Inc., Ibaraki, Japan (T.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuki Katsukura
Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan (S.O., K.N.); Laboratory of Veterinary Pathology, School of Veterinary Medicine, Azabu University, Kanagawa, Japan (H.K., J.K.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (T.I, Y.K., W.O., Y.U., T.T.); PhoenixBio, Co., Ltd., Hiroshima, Japan (C.T.); DeThree Research Laboratory Inc., Ibaraki, Japan (T.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wataru Obuchi
Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan (S.O., K.N.); Laboratory of Veterinary Pathology, School of Veterinary Medicine, Azabu University, Kanagawa, Japan (H.K., J.K.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (T.I, Y.K., W.O., Y.U., T.T.); PhoenixBio, Co., Ltd., Hiroshima, Japan (C.T.); DeThree Research Laboratory Inc., Ibaraki, Japan (T.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuo Uchida
Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan (S.O., K.N.); Laboratory of Veterinary Pathology, School of Veterinary Medicine, Azabu University, Kanagawa, Japan (H.K., J.K.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (T.I, Y.K., W.O., Y.U., T.T.); PhoenixBio, Co., Ltd., Hiroshima, Japan (C.T.); DeThree Research Laboratory Inc., Ibaraki, Japan (T.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junichi Kamiie
Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan (S.O., K.N.); Laboratory of Veterinary Pathology, School of Veterinary Medicine, Azabu University, Kanagawa, Japan (H.K., J.K.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (T.I, Y.K., W.O., Y.U., T.T.); PhoenixBio, Co., Ltd., Hiroshima, Japan (C.T.); DeThree Research Laboratory Inc., Ibaraki, Japan (T.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toru Horie
Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan (S.O., K.N.); Laboratory of Veterinary Pathology, School of Veterinary Medicine, Azabu University, Kanagawa, Japan (H.K., J.K.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (T.I, Y.K., W.O., Y.U., T.T.); PhoenixBio, Co., Ltd., Hiroshima, Japan (C.T.); DeThree Research Laboratory Inc., Ibaraki, Japan (T.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tetsuya Terasaki
Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan (S.O., K.N.); Laboratory of Veterinary Pathology, School of Veterinary Medicine, Azabu University, Kanagawa, Japan (H.K., J.K.); Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (T.I, Y.K., W.O., Y.U., T.T.); PhoenixBio, Co., Ltd., Hiroshima, Japan (C.T.); DeThree Research Laboratory Inc., Ibaraki, Japan (T.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Chimeric mice with humanized liver (PXB mice) have been generated by transplantation of urokinase-type plasminogen activator/severe combined immunodeficiency mice with human hepatocytes. The purpose of the present study was to clarify the protein expression levels of metabolizing enzymes and transporters in humanized liver of PXB mice transplanted with hepatocytes from three different donors, and to compare their protein expressions with those of human livers to validate this human liver model. The protein expression levels of metabolizing enzymes and transporters were quantified in microsomal fraction and plasma membrane fraction, respectively, by means of liquid chromatography–tandem mass spectrometry. Protein expression levels of 12 human P450 enzymes, two human UDP-glucuronosyltransferases, eight human ATP binding cassette (ABC) transporters, and eight human solute carrier transporters were determined. The variances of protein expression levels among samples from mice humanized with hepatocytes from all donors were significantly greater than those from samples obtained from mice derived from each individual donor. Compared with the protein expression levels in human livers, all of the quantified metabolizing enzymes and transporters were within a range of 4-fold difference, except for CYP2A6, CYP4A11, bile salt export pump (BSEP), and multidrug resistance protein 3 (MDR3), which showed 4- to 5-fold differences between PXB mouse and human livers. The present study indicates that humanized liver of PXB mice is a useful model of human liver from the viewpoint of protein expression of metabolizing enzymes and transporters, but the results are influenced by the characteristics of the human hepatocyte donor.

Footnotes

    • Received February 19, 2014.
    • Accepted April 7, 2014.
  • This study was supported in part by a grant by the Development of Creative Technology Seeds Supporting Program for Creating University Ventures from Japan Science and Technology Agency (JST), a grant for Strategy Promotion of Innovative Research and Development from JST, and a grant from the Industrial Technology Research Grant Program from New Energy and the Industrial Technology Development Organization (NEDO) of Japan.

  • dx.doi.org/10.1124/dmd.114.057646.

  • ↵Embedded ImageThis article has supplemental material available at dmd.aspetjournals.org.

  • Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 42 (6)
Drug Metabolism and Disposition
Vol. 42, Issue 6
1 Jun 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Validation of uPA/SCID Mouse with Humanized Liver as a Human Liver Model: Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases by LC-MS/MS
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rapid CommunicationShort Communication

Protein Levels of P450s, UGTs, and Transporters in PXB Mice

Sumio Ohtsuki, Hirotaka Kawakami, Tae Inoue, Kenji Nakamura, Chise Tateno, Yuki Katsukura, Wataru Obuchi, Yasuo Uchida, Junichi Kamiie, Toru Horie and Tetsuya Terasaki
Drug Metabolism and Disposition June 1, 2014, 42 (6) 1039-1043; DOI: https://doi.org/10.1124/dmd.114.057646

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Rapid CommunicationShort Communication

Protein Levels of P450s, UGTs, and Transporters in PXB Mice

Sumio Ohtsuki, Hirotaka Kawakami, Tae Inoue, Kenji Nakamura, Chise Tateno, Yuki Katsukura, Wataru Obuchi, Yasuo Uchida, Junichi Kamiie, Toru Horie and Tetsuya Terasaki
Drug Metabolism and Disposition June 1, 2014, 42 (6) 1039-1043; DOI: https://doi.org/10.1124/dmd.114.057646
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Preincubation Effects on Inhibition of OCT1 by CsA
  • Carbamazepine Metabolite and Hypersensitivity Reactions
  • SULT4A1 Preserves Mitochondrial Function
Show more Short Communication

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics